Company profile for Mirati Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Mirati is developing a pipeline of novel therapeutics that has the potential to improve the lives of patients, by directly targeting genetic and immunological drivers of cancer. Each program is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. One of the most important breakthroughs in cancer treatment over the last decade has focused on cancer immunotherapi...
Mirati is developing a pipeline of novel therapeutics that has the potential to improve the lives of patients, by directly targeting genetic and immunological drivers of cancer. Each program is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. One of the most important breakthroughs in cancer treatment over the last decade has focused on cancer immunotherapies that utilize the body’s own immune system to target & destroy cancer cells. Checkpoint inhibitors, a type of immunotherapy, block PD-1/PD-L1 signaling, letting the immune system do its job & target the cancer cell.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9393 Towne Centre Drive Ste 200 San Diego, CA 92121
Telephone
Telephone
858.332.3410
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.raps.org/news-and-articles/news-articles/2025/5/trends-in-opdp-research-and-recent-enforcement-act

RAPS
16 May 2025

https://www.fiercepharma.com/marketing/fda-blasts-bristol-myers-over-misleading-krazati-efficacy-claims

FIERCE PHARMA
08 Aug 2024

https://www.fiercepharma.com/pharma/bms-cuts-hundreds-mirati-staffers-months-after-closing-58b-buyout

FIERCE PHARMA
27 Mar 2024

https://www.businesswire.com/news/home/20240122035431/en

BUSINESSWIRE
23 Jan 2024

https://endpts.com/bristol-myers-gets-regulatory-clearance-to-close-mirati-deal-as-ftc-increases-pressure-on-pharma-ma/

Nicole DeFeudis ENDPTS
20 Dec 2023

https://www.prnewswire.com/news-releases/mirati-therapeutics-receives-positive-opinion-from-chmp-for-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-following-a-re-examination-proce-301984690.html

PR NEWSWIRE
11 Nov 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty